EP1144654A2 - Serinprotease - Google Patents
SerinproteaseInfo
- Publication number
- EP1144654A2 EP1144654A2 EP00962730A EP00962730A EP1144654A2 EP 1144654 A2 EP1144654 A2 EP 1144654A2 EP 00962730 A EP00962730 A EP 00962730A EP 00962730 A EP00962730 A EP 00962730A EP 1144654 A2 EP1144654 A2 EP 1144654A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- polypeptide
- hetaa37
- polynucleotide
- nucleotide sequence
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 102000012479 Serine Proteases Human genes 0.000 title description 5
- 108010022999 Serine Proteases Proteins 0.000 title description 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 198
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 192
- 229920001184 polypeptide Polymers 0.000 claims abstract description 189
- 108091033319 polynucleotide Proteins 0.000 claims abstract description 85
- 102000040430 polynucleotide Human genes 0.000 claims abstract description 85
- 239000002157 polynucleotide Substances 0.000 claims abstract description 84
- 238000000034 method Methods 0.000 claims abstract description 57
- 238000011282 treatment Methods 0.000 claims abstract description 6
- 210000004027 cell Anatomy 0.000 claims description 52
- 125000003729 nucleotide group Chemical group 0.000 claims description 52
- 239000002773 nucleotide Substances 0.000 claims description 50
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 30
- 230000000694 effects Effects 0.000 claims description 28
- 230000014509 gene expression Effects 0.000 claims description 27
- 150000001875 compounds Chemical class 0.000 claims description 24
- 239000000556 agonist Substances 0.000 claims description 15
- 201000010099 disease Diseases 0.000 claims description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 15
- 239000005557 antagonist Substances 0.000 claims description 14
- 238000004519 manufacturing process Methods 0.000 claims description 13
- 230000027455 binding Effects 0.000 claims description 10
- 230000035772 mutation Effects 0.000 claims description 9
- 239000003446 ligand Substances 0.000 claims description 8
- 239000000758 substrate Substances 0.000 claims description 8
- 230000008569 process Effects 0.000 claims description 7
- 210000000170 cell membrane Anatomy 0.000 claims description 5
- 238000001727 in vivo Methods 0.000 claims description 5
- 230000000295 complement effect Effects 0.000 claims description 4
- 102000039446 nucleic acids Human genes 0.000 claims description 4
- 108020004707 nucleic acids Proteins 0.000 claims description 4
- 150000007523 nucleic acids Chemical class 0.000 claims description 4
- 230000004044 response Effects 0.000 claims description 3
- 230000005764 inhibitory process Effects 0.000 claims description 2
- 239000012528 membrane Substances 0.000 claims description 2
- 230000000638 stimulation Effects 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims 1
- 230000001131 transforming effect Effects 0.000 claims 1
- 238000003556 assay Methods 0.000 abstract description 14
- 201000001320 Atherosclerosis Diseases 0.000 abstract description 11
- 206010061218 Inflammation Diseases 0.000 abstract description 11
- 206010028980 Neoplasm Diseases 0.000 abstract description 11
- 208000012902 Nervous system disease Diseases 0.000 abstract description 11
- 208000025966 Neurological disease Diseases 0.000 abstract description 11
- 208000006011 Stroke Diseases 0.000 abstract description 11
- 208000010399 Wasting Syndrome Diseases 0.000 abstract description 11
- 206010003246 arthritis Diseases 0.000 abstract description 11
- 208000006673 asthma Diseases 0.000 abstract description 11
- 201000011510 cancer Diseases 0.000 abstract description 11
- 206010012601 diabetes mellitus Diseases 0.000 abstract description 11
- 230000004054 inflammatory process Effects 0.000 abstract description 11
- 230000004770 neurodegeneration Effects 0.000 abstract description 11
- 208000015122 neurodegenerative disease Diseases 0.000 abstract description 11
- 238000010188 recombinant method Methods 0.000 abstract description 2
- 108090000623 proteins and genes Proteins 0.000 description 37
- 239000012634 fragment Substances 0.000 description 28
- 239000000203 mixture Substances 0.000 description 23
- 102000004169 proteins and genes Human genes 0.000 description 23
- 108020004414 DNA Proteins 0.000 description 21
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 16
- 150000001413 amino acids Chemical class 0.000 description 12
- 238000009472 formulation Methods 0.000 description 12
- 108020003175 receptors Proteins 0.000 description 11
- 102000005962 receptors Human genes 0.000 description 11
- 239000002299 complementary DNA Substances 0.000 description 9
- 239000000523 sample Substances 0.000 description 9
- 239000013598 vector Substances 0.000 description 9
- 238000013459 approach Methods 0.000 description 8
- 238000009396 hybridization Methods 0.000 description 8
- 230000002068 genetic effect Effects 0.000 description 7
- 230000004048 modification Effects 0.000 description 7
- 238000012986 modification Methods 0.000 description 7
- 238000012216 screening Methods 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 241000124008 Mammalia Species 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 108091028043 Nucleic acid sequence Proteins 0.000 description 5
- 102000035195 Peptidases Human genes 0.000 description 5
- 108091005804 Peptidases Proteins 0.000 description 5
- 239000004365 Protease Substances 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 238000012217 deletion Methods 0.000 description 5
- 230000037430 deletion Effects 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 239000003937 drug carrier Substances 0.000 description 5
- 230000028993 immune response Effects 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 229960005486 vaccine Drugs 0.000 description 5
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 4
- 108091034117 Oligonucleotide Proteins 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 4
- 230000002159 abnormal effect Effects 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 238000007792 addition Methods 0.000 description 4
- 125000000539 amino acid group Chemical group 0.000 description 4
- 230000000890 antigenic effect Effects 0.000 description 4
- 230000004071 biological effect Effects 0.000 description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 4
- 230000002759 chromosomal effect Effects 0.000 description 4
- 210000000349 chromosome Anatomy 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 238000005755 formation reaction Methods 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 238000001415 gene therapy Methods 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 4
- 230000001177 retroviral effect Effects 0.000 description 4
- 238000007423 screening assay Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 230000014616 translation Effects 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 102000006382 Ribonucleases Human genes 0.000 description 3
- 108010083644 Ribonucleases Proteins 0.000 description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 230000004075 alteration Effects 0.000 description 3
- 125000004122 cyclic group Chemical group 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 230000000069 prophylactic effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 108091026890 Coding region Proteins 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 108091060211 Expressed sequence tag Proteins 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 101001091385 Homo sapiens Kallikrein-6 Proteins 0.000 description 2
- 101001091388 Homo sapiens Kallikrein-7 Proteins 0.000 description 2
- 238000012300 Sequence Analysis Methods 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 230000000692 anti-sense effect Effects 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000008827 biological function Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 238000004590 computer program Methods 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 102000053974 human KLK6 Human genes 0.000 description 2
- 102000055383 human KLK7 Human genes 0.000 description 2
- 210000004408 hybridoma Anatomy 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 239000013600 plasmid vector Substances 0.000 description 2
- 230000004481 post-translational protein modification Effects 0.000 description 2
- 230000001323 posttranslational effect Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 238000007910 systemic administration Methods 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 238000010798 ubiquitination Methods 0.000 description 2
- 230000034512 ubiquitination Effects 0.000 description 2
- 230000009452 underexpressoin Effects 0.000 description 2
- 241001515965 unidentified phage Species 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 101150098072 20 gene Proteins 0.000 description 1
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
- 230000005730 ADP ribosylation Effects 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000700662 Fowlpox virus Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- HVLSXIKZNLPZJJ-TXZCQADKSA-N HA peptide Chemical group C([C@@H](C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 HVLSXIKZNLPZJJ-TXZCQADKSA-N 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 108010093488 His-His-His-His-His-His Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 229930010555 Inosine Natural products 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 101001091370 Mus musculus Kallikrein-8 Proteins 0.000 description 1
- 101001086281 Mus musculus Opsin-5 Proteins 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 241000256248 Spodoptera Species 0.000 description 1
- 241000295644 Staphylococcaceae Species 0.000 description 1
- 241000187747 Streptomyces Species 0.000 description 1
- 241000701093 Suid alphaherpesvirus 1 Species 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 108020004566 Transfer RNA Proteins 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 238000012870 ammonium sulfate precipitation Methods 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 238000005571 anion exchange chromatography Methods 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000010516 arginylation Effects 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000003833 bile salt Substances 0.000 description 1
- 229940093761 bile salts Drugs 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000005277 cation exchange chromatography Methods 0.000 description 1
- -1 cationic lipid Chemical class 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000012875 competitive assay Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000017858 demethylation Effects 0.000 description 1
- 238000010520 demethylation reaction Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 229960002086 dextran Drugs 0.000 description 1
- 229960000633 dextran sulfate Drugs 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 208000023965 endometrium neoplasm Diseases 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000022244 formylation Effects 0.000 description 1
- 238000006170 formylation reaction Methods 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 230000006251 gamma-carboxylation Effects 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 150000003278 haem Chemical group 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
- 210000003917 human chromosome Anatomy 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000004191 hydrophobic interaction chromatography Methods 0.000 description 1
- 238000012872 hydroxylapatite chromatography Methods 0.000 description 1
- 230000033444 hydroxylation Effects 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000026045 iodination Effects 0.000 description 1
- 238000006192 iodination reaction Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 230000007498 myristoylation Effects 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229940046166 oligodeoxynucleotide Drugs 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 210000001322 periplasm Anatomy 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229940080469 phosphocellulose Drugs 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 230000013823 prenylation Effects 0.000 description 1
- 201000001514 prostate carcinoma Diseases 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 230000009145 protein modification Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 229940043131 pyroglutamate Drugs 0.000 description 1
- 230000006340 racemization Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- YZHUMGUJCQRKBT-UHFFFAOYSA-M sodium chlorate Chemical compound [Na+].[O-]Cl(=O)=O YZHUMGUJCQRKBT-UHFFFAOYSA-M 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000019635 sulfation Effects 0.000 description 1
- 238000005670 sulfation reaction Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 238000011277 treatment modality Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- 229940038773 trisodium citrate Drugs 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Definitions
- This invention relates to newly identified polynucleotides, polypeptides encoded by them and to the use of such polynucleotides and polypeptides, and to their production. More particularly, the polynucleotides and polypeptides of the present invention relate to the serine protease family, hereinafter referred to as HETAA37. The invention also relates to inhibiting or activating the action of such polynucleotides and polypeptides.
- proteases perform a variety of important functions in human physiology. Increasingly diseases are being identified where proteases are critical for the pathology of a particular disease. For these key proteases designing or screening for selective antagonists or agonists can lead to the development of new drugs.
- the serine proteases are a major family of proteases for which a large number are known, for example; human stratum corneum chymotryptic enzyme ( Hansson et al. J Biol Chem 269, 19420-19426. 1994) mouse neuropsin, (Chen et al. JNeurosci 15:5088-5097, 1995) and human neurosin (Yamashiro et al.
- the invention relates to HETAA37 polypeptides and recombinant materials and methods for their production.
- Another aspect of the invention relates to methods for using such HETAA37 polypeptides and polynucleotides. Such uses include the treatment of cancer, inflammation, asthma, wasting diseases, atherosclerosis, stroke, diabetes, arthritis, Alzheimer's and other neurodegenerative diseases, and other neurological disorders, among others.
- the invention relates to methods to identify agonists and antagonists using the materials provided by the invention, and treating conditions associated with HETAA37 imbalance with the identified compounds.
- Yet another aspect of the invention relates to diagnostic assays for detecting diseases associated with inappropriate HETAA37 activity or levels.
- HETAA37 refers, among others, generally to a polypeptide comprising any the amino acid sequences designated by the symbols "Qt” set forth in Table 2, or an allelic variant thereof.
- HETAA37 activity or HETAA37 polypeptide activity refers to the metabolic or physiologic function of said HETAA37 including similar activities or improved activities or these activities with decreased undesirable side-effects. Also included are antigenic and immunogenic activities of said HETAA37.
- HETAA37 gene refers to a polynucleotide having the nucleotide sequence set forth in SEQ ID NO: 1 or allelic variants thereof and/or their complements.
- Antibodies as used herein includes polyclonal and monoclonal antibodies, chimeric, single chain, and humanized antibodies, as well as Fab fragments, including the products of an Fab or other immunoglobulin expression library.
- Isolated means altered “by the hand of man” from the natural state. If an "isolated” composition or substance occurs in nature, it has been changed or removed from its original environment, or both.
- a polynucleotide or a polypeptide naturally present in a living animal is not “isolated,” but the same polynucleotide or polypeptide separated from the coexisting materials of its natural state is “isolated”, as the term is employed herein.
- Polynucleotide generally refers to any polyribonucleotide or polydeoxribonucleotide, which may be unmodified RNA or DNA or modified RNA or DNA.
- Polynucleotides include, without limitation single- and double-stranded DNA, DNA that is a mixture of single- and double-stranded regions, single- and double-stranded RNA, and RNA that is mixture of single- and double-stranded regions, hybrid molecules comprising DNA and RNA that may be single- stranded or, more typically, double-stranded or a mixture of single- and double-stranded regions.
- polynucleotide refers to triple-stranded regions comprising RNA or DNA or both RNA and DNA.
- the term polynucleotide also includes DNAs or RNAs containing one or more modified bases and DNAs or RNAs with backbones modified for stability or for other reasons.
- Modified bases include, for example, tritylated bases and unusual bases such as inosine.
- polynucleotide embraces chemically, enzymatically or metabolically modified forms of polynucleotides as typically found in nature, as well as the chemical forms of DNA and RNA characteristic of viruses and cells.
- Polynucleotide also embraces relatively short polynucleotides, often referred to as oligonucleotides.
- Polypeptide refers to any peptide or protein comprising two or more amino acids joined to each other by peptide bonds or modified peptide bonds, i.e., peptide isosteres.
- Polypeptide refers to both short chains, commonly referred to as peptides, oligopeptides or oligomers, and to longer chains, generally referred to as proteins. Polypeptides may contain amino acids other than the 20 gene-encoded amino acids.
- Polypeptides include amino acid sequences modified either by natural processes, such as posttranslational processing, or by chemical modification techniques which are well known in the art. Such modifications are well described in basic texts and in more detailed monographs, as well as in a voluminous research literature.
- Modifications can occur anywhere in a polypeptide, including the peptide backbone, the amino acid side-chains and the amino or carboxyl termini. It will be appreciated that the same type of modification may be present in the same or varying degrees at several sites in a given polypeptide. Also, a given polypeptide may contain many types of modifications. Polypeptides may be branched as a result of ubiquitination, and they may be cyclic, with or without branching. Cyclic, branched and branched cyclic polypeptides may result from posttranslation natural processes or may be made by synthetic methods.
- Modifications include acetylation, acylation, ADP-ribosylation, amidation, covalent attachment of flavin, covalent attachment of a heme moiety, covalent attachment of a nucleotide or nucleotide derivative, covalent attachment of a lipid or lipid derivative, covalent attachment of phosphotidylinositol, cross-linking, cyclization, disulfide bond formation, demethylation, formation of covalent cross-links, formation of cystine, formation of pyroglutamate, formylation, gamma-carboxylation, glycosylation, GPI anchor formation, hydroxylation, iodination, methylation, myristoylation, oxidation, proteolytic processing, phosphorylation, prenylation, racemization, selenoylation, sulfation, transfer-RNA mediated addition of amino acids to proteins such as arginylation, and ubiquitination.
- Variant is a polynucleotide or polypeptide that differs from a reference polynucleotide or polypeptide respectively, but retains essential properties.
- a typical variant of a polynucleotide differs in nucleotide sequence from another, reference polynucleotide.
- Changes in the nucleotide sequence of the variant may or may not alter the amino acid sequence of a polypeptide encoded by the reference polynucleotide. Nucleotide changes may result in amino acid substitutions, additions, deletions, fusions and truncations in the polypeptide encoded by the reference sequence, as discussed below.
- a typical variant of a polypeptide differs in amino acid sequence from another, reference polypeptide. Generally, differences are limited so that the sequences of the reference polypeptide and the variant are closely similar overall and, in many regions, identical.
- a variant and reference polypeptide may differ in amino acid sequence by one or more substitutions, additions, deletions in any combination.
- a substituted or inserted amino acid residue may or may not be one encoded by the genetic code.
- a variant of a polynucleotide or polypeptide may be a naturally occurring such as an allelic variant, or it may be a variant that is not known to occur naturally.
- Non-naturally occurring variants of polynucleotides and polypeptides may be made by mutagenesis techniques or by direct synthesis. "Identity" is a measure of the identity of nucleotide sequences or amino acid sequences.
- identity is well known to skilled artisans (Carillo, H., and Lipton, D., SIAM J Applied Math (1988) 48: 1073). Methods commonly employed to determine identity or similarity between two sequences include, but are not limited to, those disclosed in Guide to Huge Computers, Martin J. Bishop, ed., Academic Press, San Diego, 1994, and Carillo, H., and Lipton, D., SIAM J Applied Math (1988) 48: 1073. Methods to determine identity and similarity are codified in computer programs.
- Preferred computer program methods to determine identity and similarity between two sequences include, but are not limited to, GCS program package (Devereux, J., et al., Nucleic Acids Research (1984) 12( 1 ):387), BLASTP, BLASTN, FASTA (Atschul, S.F. et al, JMolec Biol ( 1990) 215 :403).
- a polynucleotide having a nucleotide sequence having at least, for example, 95% "identity" to a reference nucleotide sequence of SEQ ID NO: 1 is intended that the nucleotide sequence of the polynucleotide is identical to the reference sequence except that the polynucleotide sequence may include up to five point mutations per each 100 nucleotides of the reference nucleotide sequence of SEQ ID NO: 1.
- a polynucleotide having a nucleotide sequence at least 95% identical to a reference nucleotide sequence up to 5% of the nucleotides in the reference sequence may be deleted or substituted with another nucleotide, or a number of nucleotides up to 5% of the total nucleotides in the reference sequence may be inserted into the reference sequence.
- These mutations of the reference sequence may occur at the 5 or 3 terminal positions of the reference nucleotide sequence or anywhere between those terminal positions, interspersed either individually among nucleotides in the reference sequence or in one or more contiguous groups within the reference sequence.
- polypeptide having an amino acid sequence having at least, for example, 95% "identity" to a reference amino acid sequence Qt of Table 2 is intended that the amino acid sequence of the polypeptide is identical to the reference sequence except that the polypeptide sequence may include up to five amino acid alterations per each 100 amino acids of a reference amino acid of Table 2.
- the polypeptide sequence may include up to five amino acid alterations per each 100 amino acids of a reference amino acid of Table 2.
- up to 5% of the amino acid residues in the reference sequence may be deleted or substituted with another amino acid, or a number of amino acids up to 5% of the total amino acid residues in the reference sequence may be inserted into the reference sequence.
- the present invention relates to HETAA37 polypeptides (or HETAA37 proteins).
- the HETAA37 polypeptides include any of the polypeptides designated by symbols "Qt" of Table 2; as well as polypeptides comprising an amino acid sequence Qt of Table 2; and polypeptides comprising the amino acid sequence which have at least 80% identity to any of the amino acid sequences Qt of Table 2 over its entire length, and still more preferably at least 90% identity, and even still more preferably at least 95% identity to any of those in Table 2. Furthermore, those with at least 97-99% are highly preferred.
- HETAA37 polypeptides having the amino acid sequence which have at least 80% identity to the polypeptide having any of the amino acid sequences Qt of Table 2 over its entire length, and still more preferably at least 90% identity, and still more preferably at least 95% identity to any of those in Table 2. Furthermore, those with at least 97-99% are highly preferred.
- HETAA37 polypeptides exhibit at least one biological activity of HETAA37.
- the HETAA37 polypeptides of the present invention also include a polypeptide comprising an amino acid sequence encoded by a polynucleotide that have at least 80% identity to that of SEQ ID NO: 1 over its entire length.
- the HETAA37 polypeptides may be in the form of the "mature" protein or may be a part of a larger protein such as a fusion protein. It is often advantageous to include an additional amino acid sequence which contains secretory or leader sequences, pro-sequences, sequences which aid in purification such as multiple histidine residues, or an additional sequence for stability during recombinant production.
- a fragment is a polypeptide having an amino acid sequence that entirely is the same as part, but not all, of the amino acid sequence of the aforementioned HETAA37 polypeptides.
- fragments may be "free-standing," or comprised within a larger polypeptide of which they form a part or region, most preferably as a single continuous region.
- Representative examples of polypeptide fragments of the invention include, for example, fragments from about amino acid number 1-20, 21-40, 41-60, 61-80, 81-100, and 101 to the end of HETAA37 polypeptide.
- “about” includes the particularly recited ranges larger or smaller by several, 5, 4, 3, 2 or 1 amino acid at either extreme or at both extremes.
- Preferred fragments include, for example, truncation polypeptides having the amino acid sequence of HETAA37 polypeptides, except for deletion of a continuous series of residues that includes the amino terminus, or a continuous series of residues that includes the carboxyl terminus or deletion of two continuous series of residues, one including the amino terminus and one including the carboxyl terminus.
- fragments characterized by structural or functional attributes such as fragments that comprise alpha-helix and alpha-helix forming regions, beta-sheet and beta-sheet-forming regions, turn and turn-forming regions, coil and coil-forming regions, hydrophilic regions, hydrophobic regions, alpha amphipathic regions, beta amphipathic regions, flexible regions, surface-forming regions, substrate binding region, and high antigenic index regions.
- Other preferred fragments are biologically active fragments.
- Biologically active fragments are those that mediate HETAA37 activity, including those with a similar activity or an improved activity, or with a decreased undesirable activity.
- variants of the defined sequence and fragments also form part of the present invention.
- Preferred variants are those that vary from the referents by conservative amino acid substitutions— i.e., those that substitute a residue with another of like characteristics. Typical such substitutions are among Ala, Val, Leu and He; among Ser and Thr; among the acidic residues Asp and Glu; among Asn and Gin; and among the basic residues Lys and Arg; or aromatic residues Phe and Tyr.
- Particularly preferred are variants in which several, 5- 10, 1-5, or 1-2 amino acids are substituted, deleted, or added in any combination.
- the HETAA37 polypeptides of the invention can be prepared in any suitable manner.
- Such polypeptides include isolated naturally occurring polypeptides, recombinantly produced polypeptides, synthetically produced polypeptides, or polypeptides produced by a combination of these methods. Means for preparing such polypeptides are well understood in the art.
- HETAA37 polynucleotides include isolated polynucleotides which encode theHETAA37 polypeptides and fragments, and polynucleotides closely related thereto. More specifically,HETAA37 polynucleotide of the invention include a polynucleotide comprising the nucleotide sequence contained in SEQ ID NO: l encoding a HETAA37 polypeptide Qt of Table 2, and polynucleotide having the particular sequence of SEQ ID NO: 1.
- HETAA37 polynucleotides further include a polynucleotide comprising a nucleotide sequence that has at least 80% identity over its entire length to a nucleotide sequence encoding a HETAA37 polypeptide Qt of Table 2, and a polynucleotide comprising a nucleotide sequence that is at least 80% identical to that of SEQ ID NO: 1 over its entire length.
- polynucleotides at least 90% identical are particularly preferred, and those with at least 95% are especially preferred.
- those with at least 97% are highly preferred and those with at least 98-99% are most highly preferred, with at least 99% being the most preferred.
- HETAA37 polynucleotides are a nucleotide sequence which has sufficient identity to a nucleotide sequence contained in SEQ ID NO: 1 to hybridize under conditions useable for amplification or for use as a probe or marker.
- the invention also provides polynucleotides which are complementary to all of the above HETAA37 polynucleotides.
- HETAA37 of the invention is structurally related to other proteins of theserine protease family, as shown by the results of sequencing the cDNA of Table 1 (SEQ ID NO: 1) encoding human HETAA37.
- the cDNA sequence of SEQ IDNO:l encodes polypeptides designated by symbols "Qt" of Table 2 that have homology to human stratum corneum chymotryptic enzyme ( Hansson et al. J Biol Chem 269, 19420-19426. 1994).
- Table 2 includes comparison between
- HETAA37 and its closest homologous protein Nucleotide sequence of Table 1 (SEQ ID NO: l) has about 57% identity (using BLASTN) in 386 nucleotide residues with human neurosin (Yamashiro et al. Biochim Biophys Acta 1350 : 11-14, 1997)
- HETAA37 polypeptides and polynucleotides of the present invention are expected to have, inter alia, similar biological functions/properties to their homologous polypeptides and polynucleotides, and their utility is obvious to anyone skilled in the art.
- a nucleotide sequence of a human HETAA37 SEQ ID NO: 1.
- AAATCA AAACGGCGAGGACTGCAGCCCGCACTCGCAGCCCTGGCAGGCGGCACTGGTCA 85
- One polynucleotide of the present invention encoding HETAA37 may be obtained using standard cloning and screening, from a cDNA library derived from mRNA in cells of human endometrial tumor and prostate carcinoma using the expressed sequence tag (EST) analysis (Adams, M.D., et al. Science ( 1991) 252: 1651-1656; Adams, M.D. et al, Nature, ( 1992) 555:632-634; Adams, M.D., et al, Nature (1995) 377 Supp:3- 174).
- Polynucleotides of the invention can also be obtained from natural sources such as genomic DNA libraries or can be synthesized using well known and commercially available techniques.
- the nucleotide sequence encoding a HETAA37 polypeptide of Table 2 may be identical to the polypeptide encoding sequence contained in Table 1 or it may be a sequence, which as a result of the redundancy (degeneracy) of the genetic code, also encodes a HETAA37 polypeptide of Table 2.
- the polynucleotide may include the coding sequence for the mature polypeptide or a fragment thereof, by itself; the coding sequence for the mature polypeptide or fragment in reading frame with other coding sequences, such as those encoding a leader or secretory sequence, a pre-, or pro- or prepro- protein sequence, or other fusion peptide portions.
- a marker sequence which facilitates purification of the fused polypeptide can be encoded.
- the marker sequence is a hexa-histidine peptide, as provided in the pQE vector (Qiagen, Inc.) and described in Gentzet al, Proc Natl Acad Sci USA (1989) 86:821-824, or is an HA tag.
- the polynucleotide may also contain non-coding 5 ' and 3' sequences, such as transcribed, non-translated sequences, splicing and polyadenylation signals, ribosome binding sites and sequences that stabilize mRNA.
- HETAA37 variants that comprise an amino acid sequence HETAA37 polypeptide of Table 2 in which several, 5-10, 1-5. 1-3, 1-2 or 1 amino acid residues are substituted, deleted or added, in any combination.
- the present invention further relates to polynucleotides that hybridize to the herein above- described sequences.
- the present invention especially relates to polynucleotides which hybridize under stringent conditions to the herein above-described polynucleotides.
- stringent conditions means hybridization will occur only if there is at least 80%, and preferably at least 90%, and more preferably at least 95%, yet even more preferably 97-99% identity between the sequences.
- Polynucleotides of the invention which are identical or sufficiently identical to a nucleotide sequence contained in SEQ ID NO: 1 or a fragment thereof, may be used as hybridization probes for cDNA and genomic DNA, to isolate full-length cDNAs and genomic clones encoding HETAA37 polypeptide and to isolate cDNA and genomic clones of other genes (including genes encoding homologs and orthologs from species other than human) that have a high sequence similarity to the HETAA37 gene.
- Such hybridization techniques are known to those of skill in the art.
- these nucleotide sequences are 80% identical, preferably 90% identical, more preferably 95% identical to that of the referent.
- the probes generally will comprise at least 15 nucleotides.
- such probes will have at least 30 nucleotides and may have at least 50 nucleotides. Particularly preferred probes will range between 30 and 50 nucleotides.
- HETAA37 polynucleotides of the present invention further include a nucleotide sequence comprising a nucleotide sequence that hybridize under stringent condition to a nucleotide sequence having SEQ ID NO: 1 or a fragment thereof.
- HETAA37 polypeptides are polypeptide comprising amino acid sequence encoded by nucleotide sequence obtained by the above hybridization condition.
- hybridization techniques are well known to those of skill in the art. Stringent hybridization conditions are as defined above or, alternatively, conditions under overnight incubation at 42°C in a solution comprising: 50% formamide, 5xSSC (150mM NaCl, 15mM trisodium citrate), 50 mM sodium phosphate (pH7.6), 5x Denhardt's solution, 10 % dextran sulfate, and 20 microgram/ml denatured, sheared salmon sperm DNA, followed by washing the filters in 0. lx SSC at about 65°C.
- polynucleotides and polypeptides of the present invention may be employed as research reagents and materials for discovery of treatments and diagnostics to animal and human disease.
- the present invention also relates to vectors which comprise a polynucleotide or polynucleotides of the present invention, and host cells which are genetically engineered with vectors of the invention and to the production of polypeptides of the invention by recombinant techniques.
- Cell-free translation systems can also be employed to produce such proteins using RNAs derived from the DNA constructs of the present invention.
- host cells can be genetically engineered to incorporate expression systems or portions thereof for polynucleotides of the present invention.
- Introduction of polynucleotides into host cells can be effected by methods described in many standard laboratory manuals, such as Davis et al , BASIC METHODS IN MOLECULAR BIOLOGY ( 1986) and Sambrook et al., MOLECULAR CLONING: A LABORATORY MANUAL, 2nd Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (1989) such as calcium phosphate transfection, DEAE-dextran mediated transfection, transvection, microinjection, cationic lipid-mediated transfection, electroporation, transduction, scrape loading, ballistic introduction or infection.
- bacterial cells such as streptococci, staphylococci, E. coli, Streptomyces and Bacillus subtilis cells
- fungal cells such as yeast cells and Aspergillus cells
- insect cells such as Drosophila S2 and Spodoptera Sf9 cells
- animal cells such as CHO, COS, HeLa, C127, 3T3, BHK, HEK 293 and Bowes melanoma cells
- plant cells A great variety of expression systems can be used.
- Such systems include, among others, chromosomal, episomal and virus-derived systems, e.g., vectors derived from bacterial plasmids, from bacteriophage, from transposons, from yeast episomes, from insertion elements, from yeast chromosomal elements, from viruses such as baculoviruses, papova viruses, such as SV40, vaccinia viruses, adenoviruses, fowl pox viruses, pseudorabies viruses and retroviruses, and vectors derived from combinations thereof, such as those derived from plasmid and bacteriophage genetic elements, such as cosmids and phagemids.
- the expression systems may contain control regions that regulate as well as engender expression.
- any system or vector suitable to maintain, propagate or express polynucleotides to produce a polypeptide in a host may be used.
- the appropriate nucleotide sequence may be inserted into an expression system by any of a variety of well-known and routine techniques, such as, for example, those set forth in Sambrooket al., MOLECULAR CLONING A LABORATORY MANUAL (supra).
- secretion signals may be incorporated into the desired polypeptide. These signals may be endogenous to the polypeptide or they may be heterologous signals.
- HETAA37 polypeptide is to be expressed for use in screening assays, generally, it is preferred that the polypeptide be produced at the surface of the cell. In this event, the cells may be harvested prior to use in the screening assay. If HETAA37 polypeptide is secreted into the medium, the medium can be recovered in order to recover and purify the polypeptide; if produced intracellularly, the cells must first be lysed before the polypeptide is recovered. HETAA37 polypeptides can be recovered and purified from recombinant cell cultures by well- known methods including ammonium sulfate or ethanol precipitation, acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography.
- This invention also relates to the use ofHETAA37 polynucleotides for use as diagnostic reagents. Detection of a mutated form ofHETAA37 gene associated with a dysfunction will provide a diagnostic tool that can add to or define a diagnosis of a disease or susceptibility to a disease which results from under-expression, over-expression or altered expression ofHETAA37.
- Individuals carrying mutations in theHETAA37 gene may be detected at the DNA level by a variety of techniques.
- Nucleic acids for diagnosis may be obtained from a subject's cells, such as from blood, urine, saliva, tissue biopsy or autopsy material.
- the genomic DNA may be used directly for detection or may be amplified enzymatically by using PCR or other amplification techniques prior to analysis.
- RNA or cDNA may also be used in similar fashion. Deletions and insertions can be detected by a change in size of the amplified product in comparison to the normal genotype. Point mutations can be identified by hybridizing amplified DNA to labeledHETAA37 nucleotide sequences. Perfectly matched sequences can be distinguished from mismatched duplexes by RNase digestion or by differences in melting temperatures.
- DNA sequence differences may also be detected by alterations in electrophoretic mobility of DNA fragments in gels, with or without denaturing agents, or by direct DNA sequencing. See, e.g., Myers et al, Science (1985) 230: 1242. Sequence changes at specific locations may also be revealed by nuclease protection assays, such as RNase and S 1 protection or the chemical cleavage method. See Cotton et al.. Proc Natl Acad Set USA (1985) 85: 4397-4401.
- an array of oligonucleotides probes comprising HETAA37 nucleotide sequence or fragments thereof can be constructed to conduct efficient screening of e.g., genetic mutations.
- the diagnostic assays offer a process for diagnosing or determining a susceptibility to cancer, inflammation, asthma, wasting diseases, atherosclerosis, stroke, diabetes, arthritis, Alzheimer's and other neurodegenerative diseases, and other neurological disorders through detection of mutation in theHETAA37 gene by the methods described.
- cancer, inflammation, asthma, wasting diseases, atherosclerosis, stroke, diabetes, arthritis, Alzheimer's and other neurodegenerative diseases, and other neurological disorders can be diagnosed by methods comprising determining from a sample derived from a subject an abnormally decreased or increased level of HETAA37 polypeptide or HETAA37 mRNA. Decreased or increased expression can be measured at the RNA level using any of the methods well known in the art for the quantitation of polynucleotides, such as, for example, PCR, RT-PCR, RNase protection, Northern blotting and other hybridization methods.
- Assay techniques that can be used to determine levels of a protein, such as anHETAA37 polypeptide, in a sample derived from a host are well-known to those of skill in the art. Such assay methods include radioimmunoassays, competitive-binding assays, Western Blot analysis and ELISA assays.
- the present invention relates to a diagonostic kit for a disease or suspectability to a disease, particularly cancer, inflammation, asthma, wasting diseases, atherosclerosis, stroke, diabetes, arthritis, Alzheimer's and other neurodegenerative diseases, and other neurological disorders, which comprises:
- HETAA37 polynucleotide preferably the nucleotide sequence of SEQ ID NO: 1 , or a fragment thereof ;
- HETAA37 polypeptide (c) a HETAA37 polypeptide, or a fragment thereof; or (d) an antibody to a HETAA37 polypeptide.
- kits may comprise a substantial component.
- the nucleotide sequences of the present invention are also valuable for chromosome identification.
- the sequence is specifically targeted to and can hybridize with a particular location on an individual human chromosome.
- the mapping of relevant sequences to chromosomes according to the present invention is an important first step in correlating those sequences with gene associated disease. Once a sequence has been mapped to a precise chromosomal location, the physical position of the sequence on the chromosome can be correlated with genetic map data. Such data are found, for example, in V. McKusick, Mendelian Inheritance in Man (available on line through Johns Hopkins University Welch Medical Library). The relationship between genes and diseases that have been mapped to the same chromosomal region are then identified through linkage analysis (coinheritance of physically adjacent genes).
- the differences in the cDNA or genomic sequence between affected and unaffected individuals can also be determined. If a mutation is observed in some or all of the affected individuals but not in any normal individuals, then the mutation is likely to be the causative agent of the disease.
- polypeptides of the invention or their fragments or analogs thereof, or cells expressing them can also be used as immunogens to produce antibodies immunospecific for theHETAA37 polypeptides.
- immunospecific means that the antibodies have substantiall greater affinity for the polypeptides of the invention than their affinity for other related polypeptides in the prior art.
- Antibodies generated against the HETAA37 polypeptides can be obtained by administering the polypeptides or epitope-bearing fragments, analogs or cells to an animal, preferably a nonhuman, using routine protocols.
- any technique which provides antibodies produced by continuous cell line cultures can be used. Examples include the hybridoma technique (Kohler, G. and Milstein, C, Nature (1975) 256:495-497), the trioma technique, the human B-cell hybridoma technique (Kozboret al, Immunology Today (1983) 4:72) and the EBV-hybridoma technique (Cole et al, MONOCLONAL ANTIBODIES AND CANCER THERAPY, pp.
- the above-described antibodies may be employed to isolate or to identify clones expressing the polypeptide or to purify the polypeptides by affinity chromatography.
- Antibodies against HETAA37 polypeptides may also be employed to treat cancer, inflammation, asthma, wasting diseases, atherosclerosis, stroke, diabetes, arthritis, Alzheimer's and other neurodegenerative diseases, and other neurological disorders, among others.
- Vaccines may also be employed to treat cancer, inflammation, asthma, wasting diseases, atherosclerosis, stroke, diabetes, arthritis, Alzheimer's and other neurodegenerative diseases, and other neurological disorders, among others.
- Another aspect of the invention relates to a method for inducing an immunological response in a mammal which comprises inoculating the mammal with HETAA37 polypeptide, or a fragment thereof, adequate to produce antibody and/or T cell immune response to protect said animal from cancer, inflammation, asthma, wasting diseases, atherosclerosis, stroke, diabetes, arthritis, Alzheimer's and other neurodegenerative diseases, and other neurological disorders, among others.
- Yet another aspect of the invention relates to a method of inducing immunological response in a mammal which comprises, delivering HETAA37 polypeptide via a vector directing expression of HETAA37 polynucleotide in vivo in order to induce such an immunological response to produce antibody to protect said animal from diseases.
- composition which, when introduced into a mammalian host, induces an immunological response in that mammal to a HETAA37 polypeptide wherein the composition comprises a HETAA37 polypeptide or HETAA37 gene.
- the vaccine formulation may further comprise a suitable carrier. Since HETAA37 polypeptide may be broken down in the stomach, it is preferably administered parenterally (including subcutaneous, intramuscular, intravenous, intradermal etc. injection).
- Formulations suitable for parenteral administration include aqueous and non-aqueous sterile injection solutions which may contain anti-oxidants, buffers, bacteriostats and solutes which render the formulation instonic with the blood of the recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents or thickening agents.
- the formulations may be presented in unit-dose or multi-dose containers, for example, sealed ampoules and vials and may be stored in a freeze-dried condition requiring only the addition of the sterile liquid carrier immediately prior to use.
- the vaccine formulation may also include adjuvant systems for enhancing the immunogenicity of the formulation, such as oil- in water systems and other systems known in the art. The dosage will depend on the specific activity of the vaccine and can be readily determined by routine experimentation.
- the HETAA37 polypeptide of the present invention may be employed in a screening process for compounds which activate (agonists) or inhibit activation of (antagonists, or otherwise called inhibitors) the HETAA37 polypeptide of the present invention.
- polypeptides of the invention may also be used to assess identify agonist or antagonists from, for example, cells, cell- free preparations, chemical libraries, and natural product mixtures.
- agonists or antagonists may be natural or modified substrates, ligands, enzymes, receptors, etc., as the case may be, of the polypeptide of the present invention; or may be structural or functional mimetics of the polypeptide of the present invention. See Coligan et al, Current Protocols in Immunology l(2):Chapter 5 (1991).
- HETAA37 polypeptides are responsible for many biological functions, including many pathologies. Accordingly, it is desirous to find compounds and drugs which stimulateHETAA37 polypeptide on the one hand and which can inhibit the function ofHETAA37 polypeptide on the other hand.
- agonists are employed for therapeutic and prophylactic purposes for such conditions as cancer, inflammation, asthma, wasting diseases, atherosclerosis, stroke, diabetes, arthritis, Alzheimer's and other neurodegenerative diseases, and other neurological disorders
- Antagonists may be employed for a variety of therapeutic and prophylactic purposes for such conditions as cancer, inflammation, asthma, wasting diseases, atherosclerosis, stroke, diabetes, arthritis, Alzheimer's and other neurodegenerative diseases, and other neurological disorders
- such screening procedures may involve using appropriate cells which express the HETAA37 polypeptide or respond to HETAA37 polypeptide of the present invention.
- Such cells include cells from mammals, yeast, Drosophila or E. coli.
- Cells which express the HETAA37 polypeptide (or cell membrane containing the expressed polypeptide) or respond toHETAA37 polypeptide are then contacted with a test compound to observe binding, or stimulation or inhibition of a functional response.
- the ability of the cells which were contacted with the candidate compounds is compared with the same cells which were not contacted forHETAA37 activity.
- the assays may simply test binding of a candidate compound wherein adherence to the cells bearing the HETAA37 polypeptide is detected by means of a label directly or indirectly associated with the candidate compound or in an assay involving competition with a labeled competitor. Further, these assays may test whether the candidate compound results in a signal generated by activation of the HETAA37 polypeptide, using detection systems appropriate to the cells bearing the HETAA37 polypeptide. Inhibitors of activation are generally assayed in the presence of a known agonist and the effect on activation by the agonist by the presence of the candidate compound is observed.
- the assays may simply comprise the steps of mixing a candidate compound with a solution containing a HETAA37 polypeptide to form a mixture, measuring HETAA37 activity in the mixture, and comparing the HETAA37 activity of the mixture to a standard.
- the HETAA37 cDNA, protein and antibodies to the protein may also be used to configure assays for detecting the effect of added compounds on the production of HETAA37 mRNA and protein in cells.
- an ELISA may be constructed for measuring secreted or cell associated levels of HETAA37 protein using monoclonal and polyclonal antibodies by standard methods known in the art, and this can be used to discover agents which may inhibit or enhance the production of HETAA37 (also called antagonist or agonist, respectively) from suitably manipulated cells or tissues.
- the HETAA37 protein may be used to identify membrane bound or soluble receptors, if any, through standard receptor binding techniques known in the art. These include, but are not limited to, ligand binding and crosslinking assays in which the HETAA37is labeled with a radioactive isotope (eg 1251), chemically modified (eg biotinylated), or fused to a peptide sequence suitable for detection or purification, and incubated with a source of the putative receptor (cells, cell membranes, cell supernatants, tissue extracts, bodily fluids). Other methods include biophysical techniques such as surface plasmon resonance and spectroscopy.
- a radioactive isotope eg 1251
- chemically modified eg biotinylated
- these binding assays can be used to identify agonists and antagonists of HETAA37which compete with the binding of HETAA37to its receptors, if any. Standard methods for conducting screening assays are well understood in the art. Examples of potential HETAA37 polypeptide antagonists include antibodies or.
- oligonucleotides or proteins which are closely related to the ligands, substrates, enzymes, receptors, etc. as the case may be, of the HETAA37 polypeptide, e.g., a fragment of the ligands, substrates, enzymes, receptors, etc.; or small molecules which bind to the polypetide of the present invention but do not elicit a response, so that the activity of the polypeptide is prevented.
- the present invention relates to a screening kit for identifying agonists, antagonists, ligands, receptors, substrates, enzymes, etc. for HETAA37 polypeptides; or compounds which decrease or enhance the production of HETAA37 polypeptides, which comprises:
- kits may comprise a substantial component.
- This invention provides methods of treating abnormal conditions such as, cancer, inflammation, asthma, wasting diseases, atherosclerosis, stroke, diabetes, arthritis, Alzheimer's and other neurodegenerative diseases, and other neurological disorders, related to both an excess of and insufficient amounts of HETAA37 polypeptide activity
- HETAA37 polypeptide is administered to a subject an inhibitor compound (antagonist) as heremabove described along with a pharmaceutically acceptable carrier in an amount effective to inhibit the function of the HETAA37 polypeptide, such as, for example, by blocking the binding of ligands, substrates, enzymes, receptors, etc , or by inhibiting a second signal, and thereby alleviating the abnormal condition
- soluble forms of HETAA37 polypeptides still capable of binding the ligand, substrate, enzymes, receptors, etc in competition with endogenous HETAA37 polypeptide may be administered Typical embodiments of such competitors comprise fragments of the HETAA37 polypeptide
- expression of the gene encoding endogenous HETAA37 polypeptide can be inhibited using expression blocking techniques
- Known such techniques involve the use of antisense sequences, either internally generated or separately administered See, for example, O'Connor, J Neurochem (1991) 56 560 in Oligodeoxynucleotides as Antisense Inhibitors of Gene Expression, CRC Press, Boca Raton, FL (1988)
- oligonucleotides which form triple helices with the gene can be supplied See, for example, Lee et al Nucleic Acids Res (1979) 6 3073, Cooney et al , Science (1988) 241 456, Dervan et al , Science (1991) 251 1360
- These oligomers can be administered per se or the relevant ohgomers can be expressed in vivo
- HETAA37 For treating abnormal conditions related to an under-expression ofHETAA37 and its activity, several approaches are also available One approach comprises administering to a subject a therapeutical ly effective amount of a compound which activates HETAA37 polypeptide, l e , an agonist as described above, in combination with a pharmaceutically acceptable carrier, to thereby alleviate the abnormal condition
- gene therapy may be employed to effect the endogenous production of HETAA37 by the relevant cells in the subject
- a polynucleotide of the invention may be engineered for expression in a replication defective retroviral vector, as discussed above
- the retroviral expression construct may then be isolated and introduced into a packaging cell transduced with a retroviral plasmid vector containing RNA encoding a polypeptide of the present invention such that the packaging cell now produces infectious viral particles containing the gene of interest
- These producer cells may be administered to a subject for engineering cells in vivo and expression of the polypeptide in vivo
- Peptides such as the soluble form ofHETAA37 polypeptides, and agonists and antagonist peptides or small molecules, may be formulated in combination with a suitable pharmaceutical carrier.
- a suitable pharmaceutical carrier comprise a therapeutically effective amount of the polypeptide or compound, and a pharmaceutically acceptable carrier or excipient.
- Such carriers include but are not limited to, saline, buffered saline, dextrose, water, glycerol, ethanol, and combinations thereof.
- Formulation should suit the mode of administration, and is well within the skill of the art.
- the invention further relates to pharmaceutical packs and kits comprising one or more containers filled with one or more of the ingredients of the aforementioned compositions of the invention.
- Polypeptides and other compounds of the present invention may be employed alone or in conjunction with other compounds, such as therapeutic compounds.
- Preferred forms of systemic administration of the pharmaceutical compositions include injection, typically by intravenous injection. Other injection routes, such as subcutaneous, intramuscular, or intraperitoneal, can be used. Alternative means for systemic administration include transmucosal and transdermal administration using penetrants such as bile salts or fusidic acids or other detergents.
- oral administration may also be possible. Administration of these compounds may also be topical and/or localized, in the form of salves, pastes, gels and the like.
- the dosage range required depends on the choice of peptide, the route of administration, the nature of the formulation, the nature of the subject's condition, and the judgment of the attending practitioner. Suitable dosages, however, are in the range of 0.1-100 ⁇ g/kg of subject. Wide variations in the needed dosage, however, are to be expected in view of the variety of compounds available and the differing efficiencies of various routes of administration. For example, oral administration would be expected to require higher dosages than administration by intravenous injection. Variations in these dosage levels can be adjusted using standard empirical routines for optimization, as is well understood in the art. Polypeptides used in treatment can also be generated endogenously in the subject, in treatment modalities often referred to as "gene therapy" as described above.
- cells from a subject may be engineered with a polynucleotide, such as a DNA or RNA, to encode a polypeptide ex vivo, and for example, by the use of a retroviral plasmid vector.
- a polynucleotide such as a DNA or RNA
- the cells are then introduced into the subject.
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9922835 | 1999-09-25 | ||
GBGB9922835.5A GB9922835D0 (en) | 1999-09-25 | 1999-09-25 | Novel compounds |
PCT/GB2000/003680 WO2001023587A2 (en) | 1999-09-25 | 2000-09-25 | Serine protease |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1144654A2 true EP1144654A2 (de) | 2001-10-17 |
EP1144654A3 EP1144654A3 (de) | 2002-02-27 |
Family
ID=10861681
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP00962730A Withdrawn EP1144654A3 (de) | 1999-09-25 | 2000-09-25 | Serinprotease |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP1144654A3 (de) |
GB (1) | GB9922835D0 (de) |
WO (1) | WO2001023587A2 (de) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6943236B2 (en) | 1997-02-25 | 2005-09-13 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of prostate cancer |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5955306A (en) * | 1996-09-17 | 1999-09-21 | Millenium Pharmaceuticals, Inc. | Genes encoding proteins that interact with the tub protein |
AR012035A1 (es) * | 1997-02-25 | 2000-09-27 | Corixa Corp | Metodo para detectar el cancer de prostata, metodo para monitorear el desarrollo del cancer de prostata, anticuerpo monoclonal que se une a un polipeptido, una cantidad terapeutica eficaz de anticuerpos monoclonales para preparar medicamentos y equipo para diagnostico |
DE19805633A1 (de) * | 1998-02-12 | 1999-08-19 | Basf Ag | Neue Serinprotease aus der Prostata |
-
1999
- 1999-09-25 GB GBGB9922835.5A patent/GB9922835D0/en not_active Ceased
-
2000
- 2000-09-25 EP EP00962730A patent/EP1144654A3/de not_active Withdrawn
- 2000-09-25 WO PCT/GB2000/003680 patent/WO2001023587A2/en not_active Application Discontinuation
Non-Patent Citations (1)
Title |
---|
See references of WO0123587A3 * |
Also Published As
Publication number | Publication date |
---|---|
WO2001023587A3 (en) | 2001-10-11 |
EP1144654A3 (de) | 2002-02-27 |
WO2001023587A2 (en) | 2001-04-05 |
GB9922835D0 (en) | 1999-11-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6319688B1 (en) | Polynucleotide encoding human sodium dependent phosphate transporter (IPT-1) | |
US6870030B2 (en) | Asp2 | |
EP0848062A2 (de) | Aspartylprotease ASP1 | |
EP0887414A2 (de) | Menschliche Serinproteasen HGBAB90 | |
US5922546A (en) | Human disintegrin metalloprotease KUZ gene | |
US5948669A (en) | Rat cathepsin K polynucleotide and polypeptide sequence | |
EP0854191A2 (de) | Human cardiac/gehirn tolloid-ähnliches Protein | |
US6245550B1 (en) | Cytokine family member EF-7 | |
US5837508A (en) | Membrane-type matrix metalloproteinase-5 gene | |
EP0894855A2 (de) | Menschlicher I kappa B-beta Transkriptionsfaktor | |
WO2000026374A2 (en) | Adipose specific protein | |
US5932446A (en) | Hmvab41 | |
US6657047B2 (en) | Human Pelota homolog | |
EP0881294A2 (de) | HOEFCC11, eine HAS2 Spleissvariante | |
WO1999049023A1 (en) | The cytokine family member 2-21 | |
EP0897982A2 (de) | Natiumbikarbonat Kotransporter | |
EP0894856A1 (de) | Humane sMAD3 Spleissvariante | |
WO1999021885A1 (en) | A human abc transporter-7 (habc7) gene | |
US20020019520A1 (en) | CBFBGA09: a human SL15 homolog | |
WO1999021988A1 (en) | THE HUMAN VESICLE TRAFFICKING PROTEIN SEC22b GENE OF CBFBBA01 | |
WO2001023587A2 (en) | Serine protease | |
EP0879886A2 (de) | Signalübertragungs Protein HLDAT86, das menschliche Wnt-4 Homolog | |
WO1999022006A1 (en) | CBLAFC02: A SUBUNIT OF VACUOLAR H(+)-ATPase | |
EP0892050A2 (de) | Menschliche HFIZG53 | |
EP0897979A2 (de) | Humaner SDR2 cDNS Klon |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
AX | Request for extension of the european patent |
Free format text: AL;LT;LV;MK;RO;SI |
|
XX | Miscellaneous (additional remarks) |
Free format text: DERZEIT SIND DIE WIPO-PUBLIKATIONSDATEN A3 NICHT VERFUEGBAR. |
|
PUAK | Availability of information related to the publication of the international search report |
Free format text: ORIGINAL CODE: 0009015 |
|
AK | Designated contracting states |
Kind code of ref document: A3 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
17P | Request for examination filed |
Effective date: 20020411 |
|
17Q | First examination report despatched |
Effective date: 20030509 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: 8566 |
|
18W | Application withdrawn |
Effective date: 20030620 |
|
RBV | Designated contracting states (corrected) |
Designated state(s): GB |